CVS sets a 2027 adjusted EPS target of $8.44, up 13% from 2026, driven by Aetna’s $2 billion operating income improvement.
CVS Health raised its preliminary 2027 adjusted earnings per share floor to $8.44, a 13% increase from its 2026 baseline. The company cited broad-based growth across segments, particularly Aetna’s $2 billion year-over-year improvement in adjusted operating income.
The margin recovery stems from two years of coordinated actions, including disciplined pricing and medical cost management in Medicare Advantage. CVS also highlighted operational discipline and investments in technology, positioning itself as a leader in pharmacy and GLP-1 market expansion.
Management outlined a $20 billion decade-long plan to transition from a healthcare provider to a healthcare technology business, focusing on transparency and net-cost pricing models in its Health Services segment.